Johnson and Johnson (JNJ) ニュース

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients...

Form 144 - Report of proposed sale of securities

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab) PR...

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in...

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American...

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated...

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2...

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation...

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX®...

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 PR...

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions...